Xeris Biopharma Quarterly Cash Flow Statement
NASDAQ: XERSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xeris Biopharma free cash flow
In the quarter ended Jun 30, 2026, Xeris Biopharma generated $8.3 million of operating cash flow. That left free cash flow of $8.3 million, a free-cash-flow margin of 9.0% of revenue. Free cash flow was up 4440.1% from the prior year's $182,000.
Summary generated from market data by MetaCap's automated system. Methodology
Xeris Biopharma cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -31.10M | 2.23M | 11.08M | 621.00K | -1.93M | -9.22M | -5.11M | -15.74M | -15.01M | -18.98M | -13.39M | -12.19M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 323.00K | 337.00K | 335.00K | 338.00K | 325.00K | 315.00K | 313.00K | 307.00K | 281.00K | 326.00K | 346.00K | 391.00K |
| Stock-Based Compensation | 11.07M | 4.14M | 5.27M | 7.64M | 5.01M | 4.44M | 3.60M | 6.77M | 4.23M | 3.77M | 2.77M | 2.46M |
| Change in Working Capital | -6.05M | -4.83M | -673.00K | -2.50M | -18.99M | -4.11M | -10.99M | 2.38M | -7.85M | -4.22M | 6.97M | -17.84M |
| Operating Cash Flow | 8.26M | 9.87M | 20.04M | 18.43M | 182.00K | -10.03M | 1.98M | -8.30M | -10.35M | -20.30M | 7.47M | -14.61M |
| Investing Cash Flow | -209.00K | -325.00K | -333.00K | -71.00K | -279.00K | -13.00K | 10.02M | 9.91M | 4.60M | -19.65M | 14.87M | 14.65M |
| Debt Issued | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Debt Repaid | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Financing Cash Flow | 1.94M | -8.84M | -266.00K | 13.85M | 942.00K | -3.14M | 398.00K | -83.00K | 659.00K | 35.19M | -1.23M | -72.00K |
| Net Change in Cash | 10.00M | 708.00K | 19.44M | 32.21M | 845.00K | -13.18M | 12.39M | 1.53M | -5.09M | -4.76M | 21.11M | -27.00K |
| Free Cash Flow | 8.26M | 9.87M | 20.04M | 18.43M | 182.00K | -10.03M | 1.98M | -8.30M | -10.35M | -20.30M | 7.47M | -14.61M |
This table shows 12 quarterly periods of Xeris Biopharma's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow XERS's reporting calendar. What is a cash flow statement?